Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress?

被引：2
|
作者：
Fenchel, Klaus [1 ,2 ]
Dale, Stephen P. [3 ]
Dempke, Wolfram C. M. [3 ,4 ]
机构：
[1] Med Sch Hamburg MSH, Hamburg, Germany
[2] Praxisklin Saalfeld Saale, Saalfeld, Germany
[3] Kyowa Kirin Pharmaceut Dev Ltd, Galashiels, Scotland
[4] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Haematol & Oncol, Munich, Germany
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2016年 / 5卷 / 04期
关键词：
RANDOMIZED CONTROLLED-TRIAL; MUTANT LUNG-CANCER; 1ST-LINE TREATMENT; PHASE-3; TRIAL; DOUBLE-BLIND; OPEN-LABEL; CHEMOTHERAPY; GEFITINIB; AFATINIB; ADENOCARCINOMA;
D O I：
10.21037/tlcr.2016.07.01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：373 / 376
页数：4
相关论文
共 50 条
  • [31] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Lam, Wei-Sen
    Le, Xiuning
    Eisert, Anna
    Himpe, Ulrike
    De Bondt, Charlotte
    Mazieres, Julien
    Petrini, Iacopo
    Tho, Lye Mun
    Ahmad, Azura
    Chik, Yin Kwan Jeannie
    Chung, Wai
    Lee, Kirsty
    Yang, Tsung-Ying
    Hsia, Te-Chun
    Joshi, Kirti
    Young, Louise
    Berghoff, Karin
    Vlassak, Soetkin
    Karachaliou, Niki
    van der Wekken, Anthonie
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 83 - 84
  • [32] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Ahmad, A. R.
    Tho, L. M.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T-Y.
    Le, X.
    Eisert, A. K.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Lam, W-S.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    Van der Wekken, A. J.
    Hsia, T-C.
    ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1584
  • [33] Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
    Le, X.
    Eisert, A.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Tho, L. M.
    Ahmad, A.
    Lam, W. -S.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T. -Y.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    v. d. Wekken, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S483 - S484
  • [34] Disparities in frontline treatment and overall survival in the era of targeted tyrosine kinase inhibitor therapy for chronic myeloid leukemia: 2004-2021.
    Vardell, Victoria
    Tantravahi, Srinivas Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Early rebiopsy to identify mechanisms and biomarkers of tumor cell survival following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy.
    McCoach, Caroline Elizabeth
    Merrick, Dan
    Aisner, Dara L.
    Bunn, Paul A.
    Cannidge, D. Ross
    Gao, Dexiang
    Kondo, Kimi
    Doebele, Robert Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?
    Mário Fontes-Sousa
    Helena Magalhães
    Alicia Oliveira
    Filipa Carneiro
    Filipa Palma dos Reis
    Pedro Silvestre Madeira
    Sara Meireles
    Advances in Therapy, 2022, 39 : 1107 - 1125
  • [37] Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?
    Fontes-Sousa, Mario
    Magalhaes, Helena
    Oliveira, Alicia
    Carneiro, Filipa
    dos Reis, Filipa Palma
    Madeira, Pedro Silvestre
    Meireles, Sara
    ADVANCES IN THERAPY, 2022, 39 (03) : 1107 - 1125
  • [38] Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations
    Shimoda, Yukiko
    Yoshida, Tatsuya
    Miyakoshi, Jun
    Torasawa, Masahiro
    Tateishi, Akiko
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2613 - 2621
  • [39] Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations
    Yukiko Shimoda
    Tatsuya Yoshida
    Jun Miyakoshi
    Masahiro Torasawa
    Akiko Tateishi
    Yuji Matsumoto
    Ken Masuda
    Yuki Shinno
    Yusuke Okuma
    Yasushi Goto
    Hidehito Horinouchi
    Noboru Yamamoto
    Yuichiro Ohe
    Cancer Immunology, Immunotherapy, 2023, 72 : 2613 - 2621
  • [40] Racial/ethnic disparities in hepatocellular carcinoma treatment and survival: Are we making progress?
    Makarova-Rusher, Oxana V.
    Erokhina, Katerina A.
    Duffy, Austin G.
    Ulahannan, Susanna Varkey
    Greten, Tim F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345